The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives?

The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?

That’s according to new research presented this week at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. “Historically, both cancer and aging have been ...

FILE - A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. According to research published Sunday, April 7, 2024, in the Journal of ...

The time between accelerated approval and first reporting of negative confirmatory trial results ranged from 1 year to more than 9 years. There may be “substantial delays” between when a drug is ...

(AP) — The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ ...

Accelerated biological aging may be behind why some types of cancer are on the rise in young adults, researchers find. Research presented at the American Association for Cancer Research (AACR) Annual ...

Avidity Biosciences (RNA) experienced a remarkable share price surge of ~900% from late 2023 to mid-2024. This is mainly due to the progress of three oligonucleotide candidates indicated for DMD, FSHD ...

In a recent study published in the journal Science Advances, researchers investigated the impact of early-life tobacco exposure on aging-related diseases. They found that in-utero tobacco exposure is ...

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives?